Omega-3 fatty acid monotherapy for pediatric bipolar disorder: A prospective open-label trial

Janet Wozniak, Joseph Biederman, Eric Mick, James Waxmonsky, Liisa Hantsoo, Catherine Best, Joanne E. Cluette-Brown, Michael Laposata

Research output: Contribution to journalArticle

107 Citations (Scopus)

Abstract

Background: To test the effectiveness and safety of omega-3 fatty acids (Omegabrite® brand) in the treatment of pediatric bipolar disorder (BPD). Method: Subjects (N = 20) were outpatients of both sexes, 6 to 17 years of age, with a DSM-IV diagnosis of BPD and Young Mania Rating Scale (YMRS) score of > 15 treated over an 8-week period in open-label trial with omega-3 fatty acids 1290 mg-4300 mg combined EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid). Results: Subjects experienced a statistically significant but modest 8.9 ± 2.9 point reduction in the YMRS scores (baseline YMRS = 28.9 ± 10.1; endpoint YMRS = 19.1 ± 2.6, p < 0.001). Adverse events were few and mild. Red blood cell membrane levels of EPA and DHA increased in treated subjects. Conclusions: As only 35% of these subjects had a response by the usual accepted criteria of > 50% decrease on the YMRS, omega-3 fatty acids treatment was associated with a very modest improvement in manic symptoms in children with BPD.

Original languageEnglish (US)
Pages (from-to)440-447
Number of pages8
JournalEuropean Neuropsychopharmacology
Volume17
Issue number6-7
DOIs
StatePublished - May 2007
Externally publishedYes

Fingerprint

Omega-3 Fatty Acids
Bipolar Disorder
Pediatrics
Eicosapentaenoic Acid
Docosahexaenoic Acids
Diagnostic and Statistical Manual of Mental Disorders
Outpatients
Safety
Therapeutics

Keywords

  • Bipolar disorder
  • Children
  • Mania
  • Omega-3 fatty acid
  • Pediatric
  • Treatment

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Biological Psychiatry
  • Neurology
  • Pharmacology
  • Psychology(all)

Cite this

Omega-3 fatty acid monotherapy for pediatric bipolar disorder : A prospective open-label trial. / Wozniak, Janet; Biederman, Joseph; Mick, Eric; Waxmonsky, James; Hantsoo, Liisa; Best, Catherine; Cluette-Brown, Joanne E.; Laposata, Michael.

In: European Neuropsychopharmacology, Vol. 17, No. 6-7, 05.2007, p. 440-447.

Research output: Contribution to journalArticle

Wozniak, J, Biederman, J, Mick, E, Waxmonsky, J, Hantsoo, L, Best, C, Cluette-Brown, JE & Laposata, M 2007, 'Omega-3 fatty acid monotherapy for pediatric bipolar disorder: A prospective open-label trial', European Neuropsychopharmacology, vol. 17, no. 6-7, pp. 440-447. https://doi.org/10.1016/j.euroneuro.2006.11.006
Wozniak, Janet ; Biederman, Joseph ; Mick, Eric ; Waxmonsky, James ; Hantsoo, Liisa ; Best, Catherine ; Cluette-Brown, Joanne E. ; Laposata, Michael. / Omega-3 fatty acid monotherapy for pediatric bipolar disorder : A prospective open-label trial. In: European Neuropsychopharmacology. 2007 ; Vol. 17, No. 6-7. pp. 440-447.
@article{a89fdb5223df48e2a82db31bd5617d97,
title = "Omega-3 fatty acid monotherapy for pediatric bipolar disorder: A prospective open-label trial",
abstract = "Background: To test the effectiveness and safety of omega-3 fatty acids (Omegabrite{\circledR} brand) in the treatment of pediatric bipolar disorder (BPD). Method: Subjects (N = 20) were outpatients of both sexes, 6 to 17 years of age, with a DSM-IV diagnosis of BPD and Young Mania Rating Scale (YMRS) score of > 15 treated over an 8-week period in open-label trial with omega-3 fatty acids 1290 mg-4300 mg combined EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid). Results: Subjects experienced a statistically significant but modest 8.9 ± 2.9 point reduction in the YMRS scores (baseline YMRS = 28.9 ± 10.1; endpoint YMRS = 19.1 ± 2.6, p < 0.001). Adverse events were few and mild. Red blood cell membrane levels of EPA and DHA increased in treated subjects. Conclusions: As only 35{\%} of these subjects had a response by the usual accepted criteria of > 50{\%} decrease on the YMRS, omega-3 fatty acids treatment was associated with a very modest improvement in manic symptoms in children with BPD.",
keywords = "Bipolar disorder, Children, Mania, Omega-3 fatty acid, Pediatric, Treatment",
author = "Janet Wozniak and Joseph Biederman and Eric Mick and James Waxmonsky and Liisa Hantsoo and Catherine Best and Cluette-Brown, {Joanne E.} and Michael Laposata",
year = "2007",
month = "5",
doi = "10.1016/j.euroneuro.2006.11.006",
language = "English (US)",
volume = "17",
pages = "440--447",
journal = "European Neuropsychopharmacology",
issn = "0924-977X",
publisher = "Elsevier",
number = "6-7",

}

TY - JOUR

T1 - Omega-3 fatty acid monotherapy for pediatric bipolar disorder

T2 - A prospective open-label trial

AU - Wozniak, Janet

AU - Biederman, Joseph

AU - Mick, Eric

AU - Waxmonsky, James

AU - Hantsoo, Liisa

AU - Best, Catherine

AU - Cluette-Brown, Joanne E.

AU - Laposata, Michael

PY - 2007/5

Y1 - 2007/5

N2 - Background: To test the effectiveness and safety of omega-3 fatty acids (Omegabrite® brand) in the treatment of pediatric bipolar disorder (BPD). Method: Subjects (N = 20) were outpatients of both sexes, 6 to 17 years of age, with a DSM-IV diagnosis of BPD and Young Mania Rating Scale (YMRS) score of > 15 treated over an 8-week period in open-label trial with omega-3 fatty acids 1290 mg-4300 mg combined EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid). Results: Subjects experienced a statistically significant but modest 8.9 ± 2.9 point reduction in the YMRS scores (baseline YMRS = 28.9 ± 10.1; endpoint YMRS = 19.1 ± 2.6, p < 0.001). Adverse events were few and mild. Red blood cell membrane levels of EPA and DHA increased in treated subjects. Conclusions: As only 35% of these subjects had a response by the usual accepted criteria of > 50% decrease on the YMRS, omega-3 fatty acids treatment was associated with a very modest improvement in manic symptoms in children with BPD.

AB - Background: To test the effectiveness and safety of omega-3 fatty acids (Omegabrite® brand) in the treatment of pediatric bipolar disorder (BPD). Method: Subjects (N = 20) were outpatients of both sexes, 6 to 17 years of age, with a DSM-IV diagnosis of BPD and Young Mania Rating Scale (YMRS) score of > 15 treated over an 8-week period in open-label trial with omega-3 fatty acids 1290 mg-4300 mg combined EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid). Results: Subjects experienced a statistically significant but modest 8.9 ± 2.9 point reduction in the YMRS scores (baseline YMRS = 28.9 ± 10.1; endpoint YMRS = 19.1 ± 2.6, p < 0.001). Adverse events were few and mild. Red blood cell membrane levels of EPA and DHA increased in treated subjects. Conclusions: As only 35% of these subjects had a response by the usual accepted criteria of > 50% decrease on the YMRS, omega-3 fatty acids treatment was associated with a very modest improvement in manic symptoms in children with BPD.

KW - Bipolar disorder

KW - Children

KW - Mania

KW - Omega-3 fatty acid

KW - Pediatric

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=33947704134&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947704134&partnerID=8YFLogxK

U2 - 10.1016/j.euroneuro.2006.11.006

DO - 10.1016/j.euroneuro.2006.11.006

M3 - Article

C2 - 17258897

AN - SCOPUS:33947704134

VL - 17

SP - 440

EP - 447

JO - European Neuropsychopharmacology

JF - European Neuropsychopharmacology

SN - 0924-977X

IS - 6-7

ER -